{"id":"copanlisib-bay-80-6946","safety":{"commonSideEffects":[{"rate":"55–70","effect":"Hyperglycemia"},{"rate":"40–50","effect":"Diarrhea"},{"rate":"30–40","effect":"Hypertension"},{"rate":"25–35","effect":"Nausea"},{"rate":"20–30","effect":"Fatigue"},{"rate":"15–25","effect":"Rash"},{"rate":"5–10","effect":"Pneumonitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Copanlisib inhibits all four isoforms of class I PI3K (α, β, γ, δ), which are frequently dysregulated in hematologic and solid tumors. By blocking PI3K, the drug suppresses the downstream AKT/mTOR signaling pathway, leading to reduced cell proliferation, increased apoptosis, and inhibition of tumor growth. It has shown particular activity in lymphoid malignancies where PI3K signaling is critical for survival.","oneSentence":"Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor that blocks PI3K signaling to suppress tumor cell proliferation and survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:07:42.141Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory follicular lymphoma"},{"name":"Relapsed or refractory indolent non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT04317105","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-17","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":54},{"nctId":"NCT06400238","phase":"PHASE2","title":"Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-15","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma","enrollment":35},{"nctId":"NCT05490771","phase":"PHASE2","title":"Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":35},{"nctId":"NCT03502733","phase":"PHASE1","title":"Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-08-14","conditions":"Lymphoma, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm","enrollment":64},{"nctId":"NCT04345913","phase":"PHASE1, PHASE2","title":"Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-01","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT06360588","phase":"PHASE2","title":"Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-08","conditions":"Malignant Solid Neoplasm","enrollment":22},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT03586661","phase":"PHASE1","title":"Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-04-29","conditions":"Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma","enrollment":31},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL","enrollment":33},{"nctId":"NCT03884998","phase":"PHASE1","title":"Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2019-02-26","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":27},{"nctId":"NCT03842228","phase":"PHASE1","title":"Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-11-21","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm","enrollment":39},{"nctId":"NCT04108858","phase":"PHASE1, PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":2},{"nctId":"NCT03939897","phase":"PHASE1","title":"Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-17","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma","enrollment":24},{"nctId":"NCT03711058","phase":"PHASE1, PHASE2","title":"Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-01-17","conditions":"Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor, Microsatellite Stable (MSS) Colon Cancer","enrollment":48},{"nctId":"NCT04042051","phase":"PHASE1","title":"Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer","status":"TERMINATED","sponsor":"Cancer Trials Ireland","startDate":"2019-11-12","conditions":"HER2-positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer","enrollment":2},{"nctId":"NCT03432741","phase":"PHASE1","title":"Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2018-03-27","conditions":"Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":17},{"nctId":"NCT04939272","phase":"PHASE1, PHASE2","title":"Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-06-29","conditions":"Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma","enrollment":8},{"nctId":"NCT03484819","phase":"PHASE2","title":"Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-13","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":12},{"nctId":"NCT01660451","phase":"PHASE2","title":"Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-11-19","conditions":"Lymphoma, Non-Hodgkin","enrollment":227},{"nctId":"NCT04933617","phase":"PHASE1","title":"Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-24","conditions":"Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma","enrollment":8},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT02369016","phase":"PHASE3","title":"Phase III Copanlisib in Rituximab-refractory iNHL","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-09-22","conditions":"Lymphoma, Non-Hodgkin","enrollment":25},{"nctId":"NCT05295589","phase":"PHASE2","title":"Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-30","conditions":"Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma","enrollment":""},{"nctId":"NCT03803761","phase":"PHASE1, PHASE2","title":"A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2019-02-13","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain","enrollment":""},{"nctId":"NCT04156828","phase":"PHASE1","title":"Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-03-31","conditions":"Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma","enrollment":12},{"nctId":"NCT03128619","phase":"PHASE1","title":"Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2017-08-02","conditions":"Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma","enrollment":10},{"nctId":"NCT03052933","phase":"PHASE1, PHASE2","title":"Copanlisib and Gemcitabine in Relapsed/Refractory PTCL","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2018-02-01","conditions":"Mature T-Cell and NK-Cell Neoplasm","enrollment":28},{"nctId":"NCT05010096","phase":"PHASE1","title":"BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-22","conditions":"Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Solid Neoplasm","enrollment":""},{"nctId":"NCT04155840","phase":"PHASE2","title":"Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"TERMINATED","sponsor":"University of Washington","startDate":"2020-01-31","conditions":"Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia","enrollment":1},{"nctId":"NCT02728258","phase":"PHASE2","title":"Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2016-09-16","conditions":"Endometrial Endometrioid Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma","enrollment":11},{"nctId":"NCT02631590","phase":"PHASE2","title":"Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-07-05","conditions":"Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma","enrollment":24},{"nctId":"NCT02822482","phase":"PHASE1, PHASE2","title":"Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss","status":"TERMINATED","sponsor":"UNICANCER","startDate":"2016-06","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":11},{"nctId":"NCT02253420","phase":"PHASE1","title":"COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-10-08","conditions":"Medical Oncology","enrollment":51},{"nctId":"NCT03377101","phase":"PHASE2","title":"Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2018-08-07","conditions":"Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive","enrollment":""},{"nctId":"NCT02155582","phase":"PHASE1","title":"Copanlisib Pharmacodynamic Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-08-12","conditions":"Non Hodgkin Lymphoma","enrollment":63},{"nctId":"NCT01392521","phase":"PHASE1","title":"Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-07","conditions":"Neoplasms","enrollment":64},{"nctId":"NCT02119221","phase":"PHASE1","title":"Copanlisib Mass Balance Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-02","conditions":"Healthy Volunteers","enrollment":6}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Copanlisib (BAY 80-6946)","genericName":"Copanlisib (BAY 80-6946)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor that blocks PI3K signaling to suppress tumor cell proliferation and survival. Used for Relapsed or refractory follicular lymphoma, Relapsed or refractory indolent non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}